Impact of select risk factors on treatment outcome in adults with candidemia

Autor: Richard H. Drew, Dustin Wilson, Brandon K. Hill
Rok vydání: 2019
Předmět:
mesh:Cohort Studies
medicine.medical_treatment
mesh:Neutropenia
Pharmaceutical Science
lcsh:RS1-441
Pharmacy
law.invention
Cohort Studies
law
mesh:Renal Replacement Therapy
Treatment Failure
Fluconazole
Original Research
Candida
Intensive care unit
Hospitals
Renal Replacement Therapy
Intensive Care Units
Treatment Outcome
mesh:Treatment Outcome
medicine.drug
Cohort study
medicine.medical_specialty
Neutropenia
mesh:North Carolina
mesh:Fluconazole
lcsh:Pharmacy and materia medica
mesh:Intensive Care Units
Internal medicine
mesh:Treatment Failure
medicine
North Carolina
Renal replacement therapy
University
mesh:Hospitals
business.industry
lcsh:RM1-950
Candidemia
Odds ratio
mesh:Candida
medicine.disease
Regimen
lcsh:Therapeutics. Pharmacology
Concomitant
Hospitals University
mesh:Candidemia
business
mesh:University
Zdroj: Pharmacy Practice (Granada) v.17 n.3 2019
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname
Pharmacy Practice, Vol 17, Iss 3, p 1561 (2019)
Pharmacy Practice
Pharmacy Practice (Granada), Volume: 17, Issue: 3, Article number: 1561, Published: 25 NOV 2019
Popis: Background: Studies examining relationships between patient-related factors and treatment outcome in patients with candidemia are limited and often based on all-cause mortality. Objective: Our purpose was to examine the impact of concurrent renal replacement therapy (RRT) and other pre-specified factors on treatment outcome among adults with candidemia. Methods: This Institutional Review Board (IRB)-approved, single-center, case-cohort study included patients over 18 years of age admitted to Duke University Hospital between Jun 1, 2013 and Jun 1, 2017 with a blood culture positive for Candida spp. Treatment-, patient-, and disease-specific data were collected, and outcome (success/failure) determined 90 days after the index culture. An odds ratio (OR) and 95% confidence interval (95%CI) were calculated for the following during therapy: receipt of RRT, fluconazole monotherapy regimen, intensive care unit (ICU) stay, and neutropenia. Results: Among the 112 encounters (from 110 unique patients) included, treatment failure occurred in 8/112 (7.1%). Demographics were comparable between outcome groups. Among 12 patients receiving concomitant RRT, only 1 patient failed therapy. With regard to treatment failure, no significant differences were observed with RRT (OR, 1.21; 95%CI, 0.14 – 10.75), fluconazole monotherapy regimen (OR, 1.59; 95%CI, 0.3-8.27), ICU stay (OR, 1.43; 95%CI, 0.32-6.29), and neutropenia (0 treatment failures). Conclusions: Treatment failure, receipt of concomitant RRT, and neutropenia were infrequent in patients undergoing treatment for candidemia. In our cohort, exposure to RRT, a fluconazole monotherapy regimen, ICU stay, or neutropenia during treatment did not impact treatment outcome.
Databáze: OpenAIRE